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Abstract. The incidence of pneumococcal pneumonia among adults is a key driver for the cost-effectiveness of
pneumococcal conjugate vaccine used among children. We sought to obtain more accurate incidence estimates among
adults by including results of pneumococcal urine antigen testing (UAT) from population-based pneumonia surveil-
lance in two Thai provinces. Active surveillance from 2006 to 2011 identified acute lower respiratory infection (ALRI)–
related hospital admissions. Adult cases of pneumococcal pneumonia were defined as hospitalized ALRI patients
aged ≥ 18 years with isolation of Streptococcus pneumoniae from blood or with positive UAT. Among 39,525 adult ALRI
patients, we identified 481 pneumococcal pneumonia cases (105 by blood culture, 376 by UAT only). Estimated incidence
of pneumococcal pneumonia hospitalizations was 30.5 cases per 100,000 persons per year (2.2 and 28.3 cases per 100,000
persons per year by blood culture and UAT, respectively). Incidence varied between 22.7 in 2007 and 43.5 in 2010, and
increased with age to over 150 per 100,000 persons per year among persons aged ≥ 70 years. Viral coinfections including influ-
enza A/B, respiratory syncytial virus (RSV), and adenovirus occurred in 11% (44/409) of pneumococcal pneumonia cases
tested. Use of UAT to identify cases of pneumococcal pneumonia among adults in rural Thailand substantially increases
estimates of pneumococcal pneumonia burden, thereby informing cost-effectiveness analyses and vaccine policy decisions.
INTRODUCTION
Pneumonia is a leading cause of morbidity and mortality
worldwide,1 with an estimated 120 million episodes and 1.3 mil-
lion fatalities among children.2,3 Streptococcus pneumoniae
(pneumococcus) is the most common vaccine-preventable
bacterial etiology of pneumonia, causing approximately 18%
of cases in children globally.2 Pneumococcal conjugate vac-
cines (PCVs) are highly effective at preventing vaccine-type
invasive pneumococcal disease (IPD) and radiographically
confirmed pneumonia in children.4–9
Pneumococcal pneumonia is also a leading cause of morbid-
ity and mortality among adults.8,10,11 PCV use among children
prevents acquisition of vaccine-type pneumococci, reducing
transmission to other children and adults.12,13 Most countries
with widespread PCV use in children have seen substantially
reduced rates of IPD and pneumonia among adults, a group
not targeted for vaccination.8,12,14,15 Thus, herd effects among
adults are the major drivers of cost-effectiveness estimates
when considering PCV recommendations for children.
Estimates of pneumococcal pneumonia burden among
adults in Asia are limited. In a 2009 review, annual IPD inci-
dence among adults aged ≥ 65 years in Asia ranged from
7.7 to 74.0 cases per 100,000 persons per year with case fatality
rates from 21.7% to 42.5% among published studies.16 How-
ever, most cases of pneumococcal pneumonia are not asso-
ciated with bacteremia and not counted in IPD incidence
estimates.7 Pneumococcal urine antigen testing (UAT) pro-
vides a complementary approach to detecting pneumococ-
cal disease and estimating burden among adults. UAT has
the ability to detect non-bacteremic and bacteremic pneu-
mococcal pneumonia and is 70–100% sensitive (70–80% in
most studies) and 67–100% specific (80 to > 90% in most
studies).17–23
To inform PCV policy discussions in Thailand and southeast
Asia, we aimed to improve the estimation of pneumococcal
pneumonia incidence among adults in Thailand by systemati-
cally using UAT in pneumonia surveillance. In addition, we
explored the temporal relationship between pneumococcal
pneumonia incidence and viral coinfections to assess the poten-
tial impact of other interventions such as influenza vaccines.
MATERIALS AND METHODS
Study population. In collaboration with the U.S. Centers
for Disease Control and Prevention (CDC) International
Emerging Infections Program, the Thailand Ministry of Pub-
lic Health conducted active, population-based surveillance
for pneumonia hospitalizations at all 20 acute care hospitals
in two rural provinces between 2002 and 2014.24 Sa Kaeo Prov-
ince, with a 2010 population of 555,471, borders Cambodia in
eastern Thailand. Nakhon Phanom Province, with a 2010 pop-
ulation of 583,264, borders Laos in northeastern Thailand.25
Provincial population estimates for 2010–2011 were avail-
able from the 2010 National Economic and Social Develop-
ment Board (NESDB) of Thailand.26 For 2006–2009, the 2010
NESBD age distribution was applied to the 2006–2009 NESDB
provincial population estimates to account for inconsistencies
between the 2010 and previous provincial population estimates.
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PCV is available in the private market in both provinces, but
uptake is minimal; a recent case–control pneumonia study in
children aged < 5 years found that none of the 641 community-
based controls had received PCV (unpublished data).
Acute lower respiratory infection surveillance. Surveillance
staff reviewed hospital admissions daily to identify hospitali-
zations consistent with acute lower respiratory infection
(ALRI). A case of ALRI was defined as ≥ 1 sign/symptom
of active infection (reported fever, measured temperature
> 38.2°C or < 35°C, chills, or an abnormal white blood cell
count [> 11,000 or < 3,000 cells/mL]) and ≥ 1 respiratory sign
or symptom (abnormal breath sounds, tachypnea, cough,
chest pain, hemoptysis, sputum production, or dyspnea) in a
hospitalized patient who had lived ≥ 6 months in one of the
study provinces. Patients hospitalized with ALRI more than
once within 14 days were counted as a single case. From
2002 to 2007, patients meeting the ALRI case definition who
had a chest radiograph performed within 48 hours post-
admission were eligible for enrollment in an etiology study.
From 2008 to 2012, every other ALRI case with or without a
chest radiograph was systematically sampled by ward and
admission time for enrollment. Radiographs were digitized
and interpreted by a panel of radiologists using standard
criteria as previously described.27,28 An adult case of pneu-
mococcal pneumonia was defined as a hospitalized ALRI
patient ≥ 18 years and either isolation of S. pneumoniae by
blood culture or a positive UAT (Figure 1). We assumed that
patients hospitalized with ALRI and laboratory-confirmed
pneumococcal infection had pneumonia, regardless of radio-
graphic findings.
Specimen collection and testing. Urine and nasopharyngeal
specimens were collected at enrollment from all consenting
patients in the etiology study. Urine specimens were stored
at 4–8°C before transport within 48 hours to the provincial
hospital laboratories for pneumococcal antigen testing using
Binax NOW® UAT (Binax, Portland, ME); positive results
were reported to clinicians within 12 hours. Nasopharyngeal
swab specimens were collected using polyester swabs (Puritan®,
Guilford, ME) through July 2010 and flocked swabs (FLOC
Swabs™, Copan, Murrieta, CA) thereafter. These specimens
were stored at 4–8°C for < 24 hours before being frozen at
−70°C and transported weekly on dry ice to Thailand’s National
Institutes of Health where they were tested for influenza A/B
virus, respiratory syncytial virus (RSV), and adenovirus by
real-time reverse transcription polymerase chain reaction.29
Blood cultures were collected as clinically indicated, regard-
less of etiology study enrollment.30 Blood samples were trans-
ported to the provincial hospital laboratories at 15–30°C within
24 hours and processed using BacT/ALERT® 3D microbial
detection system (bioMeriux, Hazelwood, MO) as previously
described.31 Antibiotic use before blood culture was deter-
mined by testing for serum antibiotic activity by disc assay.30–32
Ethical statement. Informed consent was obtained from
patients in the etiology study according to the protocol approved
by a CDC Institutional Review Board (no. 3754) and the
Thailand Ministry of Public Health Ethical Review Committee.
Statistical analysis. The analysis period was January 2006 to
December 2011. We compared characteristics of UAT-positive
versus UAT-negative ALRI patients using χ2 or F tests. We
calculated age-specific incidence of pneumococcal pneumonia
by dividing the number of cases in each age group by the
adult population of the two provinces.33
To account for ALRI patients not undergoing UAT, we
adjusted the age-specific incidence for the sampling frame and
non-enrollment of eligible ALRI patients. We assumed that
the proportion of ALRI patients positive by UAT in the
FIGURE 1. Flowchart of surveillance and etiology study participants among adults aged ≥ 18 years hospitalized with acute lower respiratory
infection (ALRI) in rural Thailand, 2006–2011.1 Patients meeting ALRI case definition and included in the pneumonia surveillance system.
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etiology study was the same as the proportion positive
among hospitalized ALRI patients who did not enroll in the
etiology study. Thus, the proportion of enrolled patients that
were positive by UAT was multiplied by the total number of
eligible ALRI patients within each age group to calculate an
adjusted numerator for the incidence estimates. Incidence
adjustments for 2006–2007 were stratified by those with or
without a chest radiograph, because only ALRI patients with
a chest radiograph were enrolled in the etiology study during
this period. For ALRI patients without a chest radiograph,
who did not enroll in the etiology study in 2006–2007 (not eli-
gible in those years), the average UAT percent positivity
among those without a chest radiograph from 2008 to 2011
was used for the incidence estimates. The incidence adjust-
ment applied to UAT cases only; we did not adjust incidence
attributable to blood culture–confirmed cases.
We also present monthly pneumococcal pneumonia case
counts and influenza A/B, RSV, and adenovirus percent pos-
itivity to explore pneumococcal seasonality and correlation
with viral infections.
RESULTS
From January 2006 to December 2011, 39,525 adults were
hospitalized with ALRI and 2,276 (5.8%) died. On the basis
of sampling methods, 21,668 patients were eligible for enroll-
ment in the etiology study and 10,746 enrolled (50% of eligi-
ble, 27% of all ALRI). The number and proportion of
enrolled patients was higher in Nakhon Phanom than in
Sa Kaeo for most years (Figure 2). Non-enrolled patients were
more likely to require mechanical ventilation (12% versus
6.6%) and die (6.7% versus 3.2%). The proportion with
radiographically confirmed pneumonia and with comorbid
conditions was similar between groups (data not shown).
Among 10,746 ALRI patients enrolled in the etiology
study, 411 (3.8%) had laboratory-confirmed pneumococcal
pneumonia, including 35 confirmed by blood culture (among
6,093 tested) and 376 by UAT only (among 10,056 tested);
20 (4.9%) of 411 were confirmed by both tests. When limited
to the 6,093 ALRI patients with blood culture and UAT
performed, 35 had pneumococcal pneumonia confirmed by
blood culture while 225 had positive UAT only, resulting in
6.4 cases of non-bacteremic pneumococcal pneumonia for
every bacteremic case. Among 28,779 (73%) patients with
ALRI not enrolled in the etiology study, 12,442 patients had
blood cultures performed and 70 had culture-confirmed
pneumococcal pneumonia, resulting in a total of 481 laboratory-
confirmed pneumococcal pneumonia cases among those hos-
pitalized with ALRI (N = 39,525) (Figure 1).
Of pneumococcal pneumonia patients, 40% (N = 193) were
≥ 70 years of age and 52% (N = 249) were male (Table 1).
Clinical characteristics most commonly reported included
cough (91%) and fever > 38.2°C (89%). Of the cases, 380 (79%)
had a chest radiograph, of which 74% (N = 282) had evidence
of radiographic pneumonia. Comorbidities most commonly
reported included heart disease (10%) and human immunodefi-
ciency virus infection (7%). Eighty patients (17%) required
mechanical ventilation and 52 (11%) died in the hospital.
Among the 481 laboratory-confirmed cases of pneumococcal
pneumonia, few had clinician discharge diagnoses (International
Statistical Classification of Diseases and Related Health Prob-
lems, 10th edition; ICD-10) of bacterial pneumonia (N = 40)
or S. pneumoniae infection (N = 23). Of 368 discharged cases,
19 (5.0%) were readmitted within 14 days for pneumonia-
related causes and three of these died during their readmission.
Among 10,056 ALRI patients with UAT performed, 396
(3.9%) tested positive and 9,660 were negative (Table 1).
UAT-positive patients were significantly more likely than
UAT-negative patients to be aged ≥ 60 years, to have evi-
dence of radiographic pneumonia, a smoking history, severe
disease (mechanical ventilation, death), and discharge diag-
noses consistent with pneumonia (P < 0.05). Of all patients
with laboratory-confirmed pneumococcal pneumonia, those
with blood culture–confirmed disease (N = 105) were sig-
nificantly more likely than those confirmed by UAT only
(N = 376) to have a history of liver disease (11% versus 1%)
or smoking (40% versus 24%), to have evidence of radio-
graphic pneumonia (90% versus 70%), and to be discharged
with a diagnosis of S. pneumoniae (18% versus 1%) or septi-
cemia (19% versus 3%) (P < 0.05). Cases confirmed by
blood culture were also significantly more likely to be
intubated (45% versus 9%) or to die (31% versus 5%) as
compared with those confirmed by UAT only (P < 0.05). No
culture-confirmed cases had blood collected for culture
≥ 2 days post-admission, suggesting that these infections were
not nosocomial. Among patients with serum antibiotic activ-
ity testing, significantly more with blood cultures without
pneumococcus detected had received pre-culture antibiotics
(4,358/16,645 [26%]) compared with those with blood cul-
tures positive for pneumococcus (4/89 [5%]) (P < 0.0001).
The proportion of patients with positive UAT who had
received pre-culture antibiotics (51/223 [23%]) was similar to
those with negative UAT (1,235/4,949 [25%]) (P = 0.48).
The observed 481 cases of laboratory-confirmed pneumo-
coccal pneumonia correspond to 10.1 adult pneumococcal
pneumonia hospitalizations per 100,000 persons per year in
these provinces from 2006 to 2011. After adjusting for the
sampling frame and non-enrollment of eligible ALRI patients,
the incidence rate of adult pneumococcal pneumonia hospital-
izations was 30.5 cases per 100,000 persons per year, includ-
ing 2.2 cases confirmed by blood culture and 28.3 cases
confirmed by UAT alone. Incidence increased with age from
18–29 years to ≥ 70 years for both culture-confirmed cases
FIGURE 2. Number and percent of eligible cases enrolled among
acute lower respiratory infection (ALRI) patients by province and
year in rural Thailand, 2006–2011.
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(0.8–9.1 cases per 100,000 persons per year) and for cases
overall (7.5–164.6 cases per 100,000 persons per year)
(Figure 3). Adjusted incidence (cases per 100,000 persons per
year) varied by province (35.9 in Nakhon Phanom versus
24.7 in Sa Kaeo) and by year (27.8 in 2006, 22.7 in 2007, 23.0
in 2008, 32.4 in 2009, 43.4 in 2010, and 34.0 in 2011).
To explore the potential impact of UAT test performance
on incidence estimates, we recalculated overall adjusted inci-
dence using a range of reported sensitivities and specific-
ities.17–23,34 When assuming the lowest reported sensitivity
(70%)34 and specificity of 100%, the incidence would have
been 41.3 cases per 100,000 persons per year. When assum-
ing the lowest specificity (67%)23 and sensitivity of 100%,
the incidence would have been 19.4 cases per 100,000 per-
sons per year.
Viral coinfections including influenza A/B, RSV, and ade-
novirus occurred in 11% (44/409) of pneumococcal pneumo-
nia cases tested; however, viral infection, including influenza,
was not more common among pneumococcal pneumonia
cases than among ALRI patients without evidence of pneu-
mococcal infection (Table 1). Median monthly case counts of
pneumococcal pneumonia were higher in October–March
TABLE 1








(N = 9,660) P value†
Age (years), n (%)
18–29 24 (5.0) 19 (4.8) 735 (7.6) 0.004
30–39 39 (8.1) 37 (9.3) 922 (9.5)
40–49 61 (12.6) 43 (10.9) 1,206 (12.5)
50–59 65 (13.5) 50 (12.6) 1,655 (17.1)
60–69 99 (20.6) 84 (21.2) 1,977 (20.5)
≥ 70 193 (40.1) 163 (41.2) 3,165 (32.8)
Male sex, n (%) 249 (51.8) 202 (51.0) 5,031 (52.1) 0.68
Clinical characteristics, n (%)
Fever (> 38.2°C or reported) 429 (89.2) 355 (89.7) 8,088 (83.7) 0.002
Abnormal WBC (> 11,000/mL or < 3,000/mL) 277 (62.5) 221 (61.2) 3,826 (43.8) < 0.0001
Cough 439 (91.3) 372 (93.9) 8,692 (90.0) 0.001
Sputum production 294 (61.1) 249 (62.9) 5,232 (54.2) 0.001
Hemoptysis 19 (4.0) 18 (4.6) 426 (4.4) 0.90
Chest pain 70 (14.6) 62 (15.8) 938 (9.7) < 0.0001
Dyspnea 338 (70.3) 276 (69.7) 5,306 (55.0) < 0.0001
Abnormal breath sounds 337 (70.1) 280 (70.7) 5,456 (56.5) < 0.0001
Tachypnea (based on clinical assessment) 215 (44.7) 164 (41.4) 3,396 (35.2) 0.01
Rales/crepitation‡ 246 (73.0) 199 (71.1) 2,972 (54.4) < 0.0001
Rhonchi‡ 105 (31.2) 88 (31.4) 1,524 (27.9) 0.20
Viral infections, n (%)‡
Adenovirus‡ 3/409 (0.8) 2/394 (0.5) 91/9,648 (0.9) 0.38
Respiratory syncytial virus‡ 11/405 (2.7) 11/402 (2.8) 274/9,930 (2.9) 0.95
Influenza A/B viruses‡ 30/405 (7.4) 30/390 (7.7) 971/9,518 (10.2) 0.11
Radiographic pneumonia, n (%)‡ 282/380 (74.2) 228/318 (71.7) 3,654/6,855 (53.3) < 0.0001
Medical history, n (%)
Any comorbid condition 128 (26.6) 101 (25.5) 2,375 (24.6) 0.68
Cancer 10 (2.1) 7 (1.8) 152 (1.6) 0.76
Liver disease 16 (3.3) 6 (1.5) 114 (1.2) 0.55
Renal disease 32 (6.7) 27 (6.8) 510 (5.3) 0.18
Heart disease 47 (9.8) 38 (9.6) 1,283 (13.3) 0.03
HIV 34 (7.1) 29 (7.3) 537 (5.6) 0.14
Smoking 133 (27.7) 101 (25.5) 2,056 (21.3) 0.04
Severity, n (%)
O2 requirement§ 447 (92.9) 363 (91.7) 8,775 (90.8) 0.57
Mechanical ventilation 80 (16.6) 39 (9.9) 591 (6.1) 0.003
Outcomes, n (%)
Death 52 (10.8) 25 (6.3) 261 (2.7) 0.0002
Transferred/referred 39 (8.1) 29 (7.3) 792 (8.2)
Discharge 368 (76.5) 329 (83.1) 8,402 (87.0)
Self-discharge 22 (4.6) 13 (3.3) 197 (2.0)
Discharge diagnoses, n (%)
Consistent with any pneumonia 235 (48.9) 189 (47.7) 2,397 (24.8) < 0.0001
Bacterial pneumonia, unspecified 40 (8.3) 34 (8.6) 481 (5.0) 0.001
Pneumonia due to Streptococcus pneumoniae 23 (4.8) 8 (2.0) 20 (0.2) < 0.0001
Viral pneumonia, unspecified 1 (0.2) 1 (0.3) 29 (0.3) 0.86
Other pneumonia diagnoses∥ 171 (35.6) 146 (36.9) 1,867 (19.4) < 0.0001
Septicemia 32 (6.7) 15 (3.8) 371 (3.8) 0.96
ALRI = acute lower respiratory infection; HIV = human immunodeficiency virus; UAT = urine antigen test; WBC = white blood cell.
*Among 481 pneumococcal pneumonia cases, 105 were confirmed by blood culture and 376 were confirmed by UAT only.
†Categorical variables tested by χ2 tests and continuous variables tested by F tests between UAT+ and UAT−. Bold font denotes statistical significance (P < 0.05).
‡Among those tested.
§Oxygen saturation < 92% or received oxygen supplementation.
∥Other pneumonia diagnoses included: pneumonia due to other infectious organisms, pneumonia due to Haemophilus influenzae, pneumonia unspecified, and pneumonia in diseases classi-
fied elsewhere.
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(8.4) compared with April–September (4.4) (P < 0.03) for
all years (Figure 4). In contrast, percent positivity of influ-
enza A/B and RSV was highest during August–October
(Figure 4).
DISCUSSION
By systematically incorporating the more sensitive UAT
assay into active, population-based ALRI surveillance in
Thailand, we documented an annual rate of pneumococcal
pneumonia hospitalizations among adults (30.5 cases per
100,000 persons per year) that was 14-fold higher than esti-
mates from blood culture alone (2.2 cases per 100,000 persons
per year). The highest rates were observed in persons aged
≥ 70 years. Despite this disease burden, health-care providers
seldom diagnosed bacterial pneumonia or S. pneumoniae. A
recent meta-analysis of diagnostic techniques for pneumococcal
pneumonia in adults estimated that there are at least three addi-
tional non-bacteremic pneumococcal pneumonia cases for every
bacteremic pneumonia case,35 whereas we found more than six
non-bacteremic cases per bacteremic case.
A positive UAT in the absence of a positive blood culture
may be due to the ability of UAT to detect less severe cases with
lower bacterial load missed by blood culture.22 Blood culture
sensitivity may also be more affected by pre-culture antibiotic
use. We found that pre-culture antibiotic receipt was signifi-
cantly more common among patients without pneumococcus
detected by blood culture compared with those with positive
cultures. Pre-culture antibiotic use has been reported to reduce
estimates of pneumococcal bacteremia by 32–67%.31,35 We did
FIGURE 4. Median monthly number of pneumococcal pneumonia cases and viral percent positivity among hospitalized adults with acute lower
respiratory infection (ALRI) in rural Thailand, 2006–2011.
FIGURE 3. Incidence of pneumococcal pneumonia hospitalizations by age group among adults in rural Thailand, 2006–2011. UAT = urine
antigen test.
1144 PIRALAM AND OTHERS
not find evidence of reduced UAT positivity with prior antibi-
otic use, which differs from the findings of Said and others,35
who estimated a 26% reduction.
Data on pneumococcal disease incidence in Asia are limited.
A previous study in Thailand estimated the incidence of pneu-
mococcal bacteremia hospitalizations among adults aged
≥ 65 years to be 14.2 cases per 100,000 persons per year.32 One
study in Taiwan found IPD incidence in adults ranged from 1.1
to 14.0 cases per 100,000 population.36 Published laboratory
results from the Hong Kong reported 7.7 cases of IPD per
100,000 persons per year among adults aged ≥ 65 years.37 These
published reports of IPD incidence provide limited basis for
comparison to our results because most cases of pneumococcal
pneumonia are not associated with bacteremia. A study in
Singapore estimated incidence of pneumococcal pneumonia by
hospital discharge diagnoses as 4.5 cases per 100,000 persons
per year among adults aged 15–64 years, 32.2 cases per 100,000
persons per year among adults aged 65–74 years, and 94.8 cases
per 100,000 persons per year among adults aged ≥ 75 years.38
These data lack laboratory confirmation and rely on physician
diagnosis, likely resulting in underestimates of the incidence of
pneumococcal pneumonia, which may explain why they differ
so much from rates that we have estimated in Thailand.
Concurrent viral infections ranged from 1% (adenovirus)
to 7% (influenza) of pneumococcal pneumonia cases. In the
United States, modeled data from 1995 to 2006 showed that
influenza may cause a modest increase in pneumococcal
pneumonia between 5% and 6% of invasive pneumococcal
pneumonia was associated with influenza infection.39 In the
United States and other temperate climates, pneumococcal
and influenza seasons are temporally correlated and peaks
of both are observed in November–March.40 However, we
found that peaks in influenza and RSV did not coincide with
increases in median monthly cases of pneumococcal pneumonia
in rural Thailand. Viral coinfections were not more common
among pneumococcal cases compared with viral infections in
ALRI patients without pneumococcal infection. These find-
ings point to the importance of factors other than circulating
influenza or RSV to account for seasonal patterns of pneumo-
coccal disease in this setting.
There are several limitations to our study. Although a
marked improvement over blood culture, reported UAT sen-
sitivity ranges from 70% to 80%, suggesting that we likely
missed pneumococcal cases and possibly underestimated
incidence.17–23,34 Although UAT specificity is generally high,
false positives also may have occurred17–23,34; the duration of
UAT positivity after pneumococcal infection is unclear but
has been documented for up to 6 weeks, so a positive UAT
could represent past rather than present infection.19 In a sen-
sitivity analysis, applying the lowest reported UAT sensitivity
(70%)34 and specificity (67%),23 pneumococcal pneumonia
incidence ranged from 19.4 to 41.3 cases per 100,000 persons
per year.17–23,34 Only 50% of patients selected for potential
enrollment (27% of all ALRI patients) were enrolled in the
study. Non-enrollment was partially due to lack of study staff
on weekends and difficulties enrolling severely ill patients,
both of which could have biased our results. Our incidence
calculations relied on the assumption that UAT percent posi-
tivity among those tested in the study was similar to those
who met the ALRI case definition but were not enrolled and
tested. Compared with ARLI patients enrolled in the etiology
study, those that did not enroll were more likely to require
mechanical ventilation or die, which could have resulted in
underestimated pneumococcal pneumonia incidence, given
the association of UAT positivity and disease severity.
Our findings offer a more accurate estimate of pneumo-
coccal pneumonia incidence among adults in Thailand, which
is critical for informing vaccine policy discussions and cost-
effectiveness analyses surrounding PCV introduction. A pre-
vious cost-effectiveness analysis of PCVs in Thailand relied
on passive national surveillance for adult pneumococcal pneu-
monia incidence. At the time, the available data found two
cases per 100,000 persons per year among persons aged 15–
24 years up to 40 cases per 100,000 persons per year among
persons aged ≥ 65 years.41 Our estimates were substantially
higher, ranging from 7.5 to 164.6 cases per 100,000 persons
per year among adults aged 18–29 years to ≥ 70 years, respec-
tively. In addition to the contribution of UAT, we identified
patients for testing through active ALRI surveillance, pro-
viding more robust estimates of disease burden compared
with passive surveillance.41 PCV is rarely used in Thailand;
our estimates suggest a substantially greater opportunity for
PCV’s indirect effects (i.e., prevention of disease in adults by
vaccinating children) in Thailand than previously estimated.
Furthermore, recent data from a large randomized placebo-
controlled trial (CAPiTA trial) among adults ≥ 65, which
also used a UAT (different assay) for case detection, found
approximately 46% efficacy of PCV13 against vaccine-type
pneumococcal pneumonia, which shows the potential direct
benefit of PCV13 in the prevention of pneumococcal pneumo-
nia among adults in addition to the indirect benefits to adults
from vaccinating children.42 Incidence estimates incorporating
UAT could be used in future PCV cost-effectiveness analyses
and inform vaccine policy decisions in Thailand and through-
out southeast Asia.
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